Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Khandan Keyomarsi

Showing results (61-70 of 105) with videos related to

Pageof 11
Sort By:
Breast Cancer Research and Treatment|June 23, 2011
Targeting low molecular weight cyclin E (LMW-E) in breast cancerAngela Nanos-Webb, Natalie A Jabbour, Asha S Multani, et al.
Molecular Cancer Therapeutics|June 17, 2017
CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle ArrestAshleigh M Francis, Angela Alexander, Yanna Liu, et al.
Oncogene|November 7, 2022
Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancerMi Li, Spiridon Tsavachidis, Fuchenchu Wang, et al.
Breast Cancer Research : BCR|January 17, 2013
Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancerKelly K Hunt, Hannah Wingate, Tomoya Yokota, et al.
International Journal of Cancer|February 8, 2022
Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional studyMin Jin Ha, Akshara Singareeka Raghavendra, Nicole M Kettner, et al.
NPJ Breast Cancer|January 26, 2025
Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2- breast cancerAkshara Singareeka Raghavendra, Nicole M Kettner, Danielle Kwiatkowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2017
Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast CancerIman Doostan, Cansu Karakas, Mehrnoosh Kohansal, et al.
Cancer Research|November 29, 2017
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast CancerJason P W Carey, Cansu Karakas, Tuyen Bui, et al.
Molecular Cancer Therapeutics|October 5, 2023
Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung MetastasisAmriti R Lulla, Said Akli, Cansu Karakas, et al.
Molecular Cancer|February 15, 2025
Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancerLinjie Luo, Peng Yang, Sofia Mastoraki, et al.
Pageof 11

Showing results (61-70 of 105) with videos related to

Sort By:
Pageof 11
Breast Cancer Research and Treatment|June 23, 2011
Targeting low molecular weight cyclin E (LMW-E) in breast cancerAngela Nanos-Webb, Natalie A Jabbour, Asha S Multani, et al.
Molecular Cancer Therapeutics|June 17, 2017
CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle ArrestAshleigh M Francis, Angela Alexander, Yanna Liu, et al.
Oncogene|November 7, 2022
Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancerMi Li, Spiridon Tsavachidis, Fuchenchu Wang, et al.
Breast Cancer Research : BCR|January 17, 2013
Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancerKelly K Hunt, Hannah Wingate, Tomoya Yokota, et al.
International Journal of Cancer|February 8, 2022
Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional studyMin Jin Ha, Akshara Singareeka Raghavendra, Nicole M Kettner, et al.
NPJ Breast Cancer|January 26, 2025
Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2- breast cancerAkshara Singareeka Raghavendra, Nicole M Kettner, Danielle Kwiatkowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2017
Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast CancerIman Doostan, Cansu Karakas, Mehrnoosh Kohansal, et al.
Cancer Research|November 29, 2017
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast CancerJason P W Carey, Cansu Karakas, Tuyen Bui, et al.
Molecular Cancer Therapeutics|October 5, 2023
Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung MetastasisAmriti R Lulla, Said Akli, Cansu Karakas, et al.
Molecular Cancer|February 15, 2025
Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancerLinjie Luo, Peng Yang, Sofia Mastoraki, et al.
Pageof 11